Greater Occipital Nerve Blockade and Sphenopalatine Ganglion Blockade in Patients With Episodic Migraine

Not Applicable

Completed

• Conditions: Greater Occipital Nerve Block; Sphenopalatine Ganglion Block; Episodic Migraine

• Registration Number: NCT06997562
• Lead Sponsor: New Valley University

Brief Summary

This study compares the effectiveness of greater occipital nerve blockade and sphenopalatine ganglion blockade in reducing headache intensity, duration, frequency, and disability in patients with episodic migraine.

Detailed Description

Migraine is a chronic neurological disorder characterized by recurrent headaches, affecting millions globally. Peripheral nerve blocks such as Greater Occipital Nerve (GON) and Sphenopalatine Ganglion (SPG) blockade have emerged as promising non-pharmacologic treatments.

Study Timeline

• Study Start: 2024-05-01
• Status Verified: 2025-05
• Primary Completion: 2025-05-03
• Study Completion: 2025-05-03
• Study First Submitted: 2025-05-21
• Study First Submitted QC: 2025-05-21
• Last Update Submitted: 2025-05-21
• Study First Posted: 2025-05-30
• Last Update Posted: 2025-05-30

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• Adults aged 18-65 years.
• Both sexes.
• Diagnosed with episodic migraine per the International Classification of Headache Disorders, 3rd edition (ICHD-3).
• Failure to achieve adequate relief with at least one prophylactic migraine treatment.

Exclusion Criteria

• Chronic migraine (≥15 headache days per month).
• History of nerve blocks within the last 6 months.
• Known allergy to anesthetic agents.
• Pregnancy or lactation.
• Active psychiatric conditions affecting compliance.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Degree of headache intensity	3 months post-procedure	Reduction in headache intensity will be recorded using numeric rating scale (NRS). Each patient will be instructed about pain assessment with NRS score. NRS (0 represents "no pain" while 10 represents "the worst pain imaginable").

Secondary Outcome Measures

Name	Time	Method
Migraine disability assessment score	3 months post-procedure	The migraine disability assessment scores are as follows: little or no disability, 5 to 10; moderate disability, 1 to 20; and severe disability, more than 20.
Headache duration	3 months post-procedure	Headache duration will be recorded.
Headache frequency	3 months post-procedure	Headache frequency will be recorded.

Trial Locations

Locations (1)

New Valley University; 🇪🇬 New Valley, Egypt

New Valley University

🇪🇬New Valley, Egypt